Tirzepatide
Mounjaro · Zepbound
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration.
Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.
Regulatory status
FDA approved
The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
~5 days (~120 h), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
What the label says about other medicines
The approved label for Tirzepatide carries 2 transcribed notes, each restating a numbered section rather than offering advice of our own.
References
- FDA approvals: Mounjaro (2022), Zepbound (2023)
- Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024
Read the source
Common questions
Tirzepatide, answered plainly.
01What is Tirzepatide?+
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration. It is also referred to as Mounjaro, Zepbound. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.
02Is Tirzepatide FDA approved?+
FDA approved. The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
03What is the half-life of Tirzepatide?+
~5 days (~120 h), subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is Tirzepatide stored and handled?+
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
05What does the Tirzepatide label say about other medicines?+
The approved label carries 2 transcribed notes covering other oral medications, insulin and insulin secretagogues. Each one restates a numbered section of the label rather than offering advice of our own. Absence of a topic means nothing was transcribed, not that a combination is safe.
06What vial strengths of Tirzepatide are commonly sold?+
Commonly listed vial strengths are 5, 10, 15, 20, 30, 60 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.
Compare Tirzepatide
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.